|
[1]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and treatment of cholestasis liver diseases[J].J Clin Hepatol, 2015, 31 (12) :1989-1999. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.胆汁淤积性肝病诊断和治疗共识[J].临床肝胆病杂志, 2015, 31 (12) :1989-1999.
|
|
[2]YU YC, MAO YM, CHEN CW, et al.CSH guideline for the diagnosis and treatment of drug-induced liver injury[J].Hepatol Int, 2017, 11 (3) :221-241.
|
|
[3]National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association.Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J].J Clin Hepatol, 2018, 34 (5) :939-946. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :939-946.
|
|
[4]European Association for the Study of the Liver.EASL clinical practice guidelines:Management of alcohol-related liver disease[J].J Hepatol, 2018, 69 (1) :154-181.
|
|
[5]European Association for the Study of the Liver.EASL clinical practice guidelines on hepatitis E virus infection[J].J Hepatol, 2018, 68 (6) :1256-1271.
|
|
[6]HOU JL, WANG GQ, WANG FS, et al.Guideline of prevention and treatment for chronic hepatitis B (2015 update) [J].JClin Transl Hepatol, 2017, 5 (4) :297-318.
|
|
[7]HIRSCHFIELD GM, DYSON JK, ALEXANDER GJM, et al.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J].Gut, 2018, 67 (9) :1568-1594.
|
|
[8]ISAYAMA H, TAZUMA S, KOKUDO N, et al.Clinical guidelines for primary sclerosing cholangitis 2017[J].J Gastroenterol, 2018, 53 (9) :1006-1034.
|
|
[9]POLLHEIMER MJ, FICKERT P, STIEGER B.Chronic cholestatic liver diseases:Clues from histopathology for pathogenesis[J].Mol Aspects Med, 2014, 37:35-56.
|
|
[10]STICOVA E, JIRSA M, PAWOWSKA J.New Insights in genetic cholestasis:From molecular mechanisms to clinical implications[J].Can J Gastroenterol Hepatol, 2018, 2018:2313675.
|
|
[11]JANSEN PL, GHALLAB A, VARTAK N, et al.The ascending pathophysiology of cholestatic liver disease[J].Hepatology, 2017, 65 (2) :722-738.
|
|
[12]GONZLEZ-REGUEIRO JA, MORENO-CASTAEDA L, URIBEM, et al.The role of bile acids in glucose metabolism and their relation with diabetes[J].Ann Hepatol, 2017, 16 (Suppl 1) :16-21.
|
|
[13]TRAUNER M, CLAUDEL T, FICKERT P, et al.Bile acids as regulators of hepatic lipid and glucose metabolism[J].Dig Dis, 2010, 28 (1) :220-224.
|
|
[14]WELLS RG, SCHWABE RF.Origin and function of myofibroblasts in the liver[J].Semin Liver Dis, 2015, 35 (2) :97-106.
|
|
[15] LI Y, TANG R, LEUNG PSC, et al.Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases[J].Autoimmun Rev, 2017, 16 (9) :885-896.
|
|
[16]LIU HX, KEANE R, SHENG L, et al.Implications of microbiota and bile acid in liver injury and regeneration[J].J Hepatol, 2015, 63 (6) :1502-1510.
|
|
[17]RAMREZ-PREZ O, CRUZ-RAMN V, CHINCHILLA-LPEZ P, et al.The role of the gut microbiota in bile acid metabolism[J].Ann Hepatol, 2017, 16 (Suppl 1) :s15-s20.
|
|
[18]DI CIAULA A, GARRUTI G, LUNARDI BACCETTO R, et al.Bile acid physiology[J].Ann Hepatol, 2017, 16 (Suppl 1) :s4-s14.
|
|
[19]NIE YF, HU J, YAN XH.Cross-talk between bile acids and intestinal microbiota in host metabolism and health[J].J Zhejiang Univ Sci B, 2015, 16 (6) :436-446.
|
|
[20] TILG H, CANI PD, MAYER EA.Gut microbiome and liver diseases[J].Gut, 2016, 65 (12) :2035-2044.
|
|
[21]MATSUBARA T, LI F, GONZALEZ FJ.FXR signaling in the enterohepatic system[J].Mol Cell Endocrinol, 2013, 368 (1-2) :17-29.
|
|
[22]TABIBIAN JH, TALWALKAR JA, LINDOR KD.Role of the microbiota and antibiotics in primary sclerosing cholangitis[J].Biomed Res Int, 2013, 2013:389537.
|
|
[23] DANAN G, TESCHKE R.RUCAM in drug and herb induced liver injury:The update[J].Int J Mol Sci, 2016, 17 (1) :14.
|
|
[24]Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guideline for diagnosis and treatment of liver failure[J].J Clin Hepatol, 2019, 35 (1) :38-44. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2018年版) [J].临床肝胆病杂志, 2019, 35 (1) :38-44.
|
|
[25]HERNAEZ R, SOLE, MOREAU R, et al.Acute-on-chronic liver failure:An update[J].Gut, 2017, 66 (3) :541-553.
|
|
[26]European Association for the Study of the Liver.EASL clinical practical guidelines on the management of acute (fulminant) liver failure[J].J Hepatol, 2017, 66 (5) :1047-1081.
|
|
[27]European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.
|
|
[28]OLSSON R, BOBERG KM, de MUCKADELL OS, et al.Highdose ursodeoxycholic acid in primary sclerosing cholangitis:A5-year multicenter, randomized, controlled study[J].Gastroenterology, 2005, 129 (5) :1464-1472.
|
|
[29] European Association for the Study of the Liver.EASL clinical practice guidelines:The diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.
|
|
[30]TRAUNER M, FUCHS CD, HALILBASIC E, et al.New therapeutic concepts in bile acid transport and signaling for management of cholestasis[J].Hepatology, 2017, 65 (4) :1393-1404.
|
|
[31]KOWDLEY KV, LUKETIC V, CHAPMAN R, et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J].Hepatology, 2018, 67 (5) :1890-1902.
|
|
[32]CHEUNG AC, LAZARIDIS KN, LARUSSO NF, et al.Emerging pharmacologic therapies for primary sclerosing cholangitis[J].Curr Opin Gastroenterol, 2017, 33 (3) :149-157.
|
|
[33]GOLDSTEIN J, LEVY C.Novel and emerging therapies for cholestatic liver diseases[J].Liver Int, 2018, 38 (9) :1520-1535.
|
|
[34]de VRIES E, BEUERS U.Management of cholestatic disease in 2017[J].Liver Int, 2017, 37 (Suppl 1) :123-129.
|
|
[35] CORPECHOT C, CHAZOUILLRES O, ROUSSEAU A, et al.A placebo-controlled trial of bezafibrate in primary biliary cholangitis[J].N Engl J Med, 2018, 378 (23) :2171-2181.
|
|
[36]JONES D, BOUDES PF, SWAIN MG, et al.Seladelpar (MBX-8025) , a selective PPAR-δagonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid:A double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study[J].Lancet Gastroenterol Hepatol, 2017, 2 (10) :716-726.
|
|
[37]BEUERS U, TRAUNER M, JANSEN P, et al.New paradigms in the treatment of hepatic cholestasis:From UDCA to FXR, PXRand beyond[J].J Hepatol, 2015, 62 (Suppl 1) :s25-s37.
|
DownLoad: